Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.9 USD | +1.03% | +0.85% | +16.83% |
05-15 | Wells Fargo Starts WAVE Life Sciences With Overweight Rating, $11 Price Target | MT |
05-09 | Transcript : Wave Life Sciences Ltd., Q1 2024 Earnings Call, May 09, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+16.83% | 715M | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- WVE Stock
- News Wave Life Sciences Ltd.
- Wave Life Sciences : Mizuho Adjusts WAVE Life Sciences' PT to $7 From $21 on Trial Data for WVE-120102, 120101 in Huntington's Disease; Buy Rating Kept